Literature DB >> 1941618

Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus.

D W Hein1, T D Rustan, K D Bucher, L S Miller.   

Abstract

A number of human epidemiological investigations suggest a relationship between acetylator phenotype and the incidence and/or severity of tumors caused by exposure to arylamine carcinogens. Conclusions drawn from these investigations can be compromised by a variety of environmental and other genetic factors. To eliminate variability in these other factors, our laboratory recently completed construction of homozygous rapid (Bio. 82.73/H-Patr), heterozygous intermediate (Bio. 82.73/H-Patr/Pat(s)) and homozygous slow (Bio. 82.73/H-Pat(s)) acetylator congenic hamsters. The purpose of the present study was to assess the utility of this congenic hamster model for investigations into the relationship between acetylator genotype and arylamine carcinogenesis. We report the expression of acetylator genotype-dependent (polymorphic) and acetylator genotype-independent (monomorphic) N-acetyltransferase isozymes in hepatic cytosols. The hepatic polymorphic N-acetyltransferase isozyme isolated from the congenic hamsters expressed clearly acetylator-genotype dependent (Patr greater than Patr/Pat(s) greater than Pat(s)) N-acetylation towards p-aminobenzoic acid, 4-aminobiphenyl, 2-aminofluorene, p-aminophenol, 1-aminopyrene, 5-aminosalicylic acid, beta-naphthylamine, 3,4-dichloroaniline, 3,2'-dimethyl-4-aminobiphenyl and p-phenetidine. Acetylator genotype-dependent N-acetylation for a number of arylamines also was observed in liver, colon, kidney and urinary bladder cytosols derived from the congenic hamster lines, including arylamines highly carcinogenic to hamster colon and urinary bladders. It is concluded that the congenic hamster model will be useful in studies to delineate the role of acetylator genotype in the incidence or severity of arylamine tumors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941618

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.

Authors:  Mark A Doll; Yu Zang; Timothy Moeller; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

2.  N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice.

Authors:  Jennifer A Loehle; Valerie Cornish; Larissa Wakefield; Mark A Doll; Jason R Neale; Yu Zang; Edith Sim; David W Hein
Journal:  J Pharmacol Exp Ther       Date:  2006-07-20       Impact factor: 4.030

3.  Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2011-11-17       Impact factor: 2.533

4.  Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat.

Authors:  David W Hein; Jean Bendaly; Jason R Neale; Mark A Doll
Journal:  Drug Metab Dispos       Date:  2008-09-17       Impact factor: 3.922

Review 5.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

6.  Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol.

Authors:  J W Rodriguez; W G Kirlin; R J Ferguson; M A Doll; K Gray; T D Rustan; M E Lee; K Kemp; P Urso; D W Hein
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

7.  Human arylamine N-acetyltransferase 2 genotype-dependent protein expression in cryopreserved human hepatocytes.

Authors:  Raúl A Salazar-González; Mark A Doll; David W Hein
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.